• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

华法林:历史、互变异构和活性。

Warfarin: history, tautomerism and activity.

机构信息

Global Pharmaceutics and Life Cycle Technology, Dept. R43D, Bldg. AP31, Abbott Laboratories, 200 Abbott Park Road, Abbott Park, IL 60064, USA.

出版信息

J Comput Aided Mol Des. 2010 Jun;24(6-7):553-73. doi: 10.1007/s10822-010-9335-7. Epub 2010 Mar 30.

DOI:10.1007/s10822-010-9335-7
PMID:20352297
Abstract

The anticoagulant drug warfarin, normally administered as the racemate, can exist in solution in potentially as many as 40 topologically distinct tautomeric forms. Only 11 of these forms for each enantiomer can be distinguished by selected computational software commonly used to estimate octanol-water partition coefficients and/or ionization constants. The history of studies on warfarin tautomerism is reviewed, along with the implications of tautomerism to its biological properties (activity, protein binding and metabolism) and chemical properties (log P, log D, pK (a)). Experimental approaches to assessing warfarin tautomerism and computational results for different tautomeric forms are presented.

摘要

抗凝药物华法林通常以外消旋体给药,在溶液中可能存在多达 40 种潜在拓扑上不同的互变异构形式。对于每个对映异构体,通常用于估计辛醇-水分配系数和/或离解常数的选定计算软件只能区分其中的 11 种形式。本文回顾了华法林互变异构的研究历史,以及互变异构对其生物学性质(活性、蛋白结合和代谢)和化学性质(log P、log D、pK(a))的影响。本文还介绍了评估华法林互变异构的实验方法和不同互变异构形式的计算结果。

相似文献

1
Warfarin: history, tautomerism and activity.华法林:历史、互变异构和活性。
J Comput Aided Mol Des. 2010 Jun;24(6-7):553-73. doi: 10.1007/s10822-010-9335-7. Epub 2010 Mar 30.
2
Tautomerism of Warfarin: Combined Chemoinformatics, Quantum Chemical, and NMR Investigation.华法林的互变异构:化学信息学、量子化学与核磁共振联合研究
J Org Chem. 2015 Oct 16;80(20):9900-9. doi: 10.1021/acs.joc.5b01370. Epub 2015 Sep 25.
3
Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.苯丙香豆素和华法林在CYP2C9活性位点代谢的结构形式。
Arch Biochem Biophys. 1999 Dec 1;372(1):16-28. doi: 10.1006/abbi.1999.1468.
4
Predicting the Prevalence of Alternative Warfarin Tautomers in Solution.预测溶液中替代华法林互变异构体的流行度。
J Chem Theory Comput. 2018 Aug 14;14(8):4405-4415. doi: 10.1021/acs.jctc.8b00453. Epub 2018 Jul 25.
5
Effect of 5-fluorouracil on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats.5-氟尿嘧啶对大鼠华法林对映体抗凝活性及药代动力学的影响。
Eur J Pharm Sci. 2002 Oct;17(1-2):73-80. doi: 10.1016/s0928-0987(02)00148-3.
6
The characterization of potent novel warfarin analogs.强效新型华法林类似物的特性
Thromb Res. 1997 Oct 15;88(2):127-36. doi: 10.1016/s0049-3848(97)00224-7.
7
Assessing the relative potency of (S)- and (R)-warfarin with a new PK-PD model, in relation to VKORC1 genotypes.使用一种新的药代动力学-药效学模型评估(S)-和(R)-华法林的相对效价,与维生素K环氧化物还原酶复合体亚单位1(VKORC1)基因型的关系。
Eur J Clin Pharmacol. 2017 Jun;73(6):699-707. doi: 10.1007/s00228-017-2248-9. Epub 2017 Apr 5.
8
Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.羟基香豆素代谢物能强烈抑制 S-华法林的 CYP2C9 代谢。
Chem Res Toxicol. 2010 May 17;23(5):939-45. doi: 10.1021/tx1000283.
9
Secreted protein profile from HepG2 cells incubated by S(-) and R(+) enantiomers of chiral drug warfarin - An analysis in cell-based system and clinical samples.基于细胞体系和临床样本分析华法林对映体孵育 HepG2 细胞后的分泌蛋白图谱。
Proteomics Clin Appl. 2010 Nov;4(10-11):808-15. doi: 10.1002/prca.201000027.
10
Enzymatic shunting: resolving the acetaminophen-warfarin controversy.
Pharmacotherapy. 2000 Dec;20(12):1464-8. doi: 10.1592/phco.20.19.1464.34860.

引用本文的文献

1
What impact does tautomerism have on drug discovery and development?互变异构对药物发现与开发有何影响?
Expert Opin Drug Discov. 2024 Sep;19(9):1011-1016. doi: 10.1080/17460441.2024.2379873. Epub 2024 Jul 16.
2
A physiologically-based pharmacokinetic/pharmacodynamic modeling approach for drug-drug-gene interaction evaluation of S-warfarin with fluconazole.基于生理的药代动力学/药效动力学模型在氟康唑与 S-华法林药物-药物-基因相互作用评价中的应用。
CPT Pharmacometrics Syst Pharmacol. 2024 May;13(5):853-869. doi: 10.1002/psp4.13123. Epub 2024 Mar 15.
3
Structural basis of antagonizing the vitamin K catalytic cycle for anticoagulation.

本文引用的文献

1
Comparison of nine programs predicting pK(a) values of pharmaceutical substances.九种预测药物物质 pK(a) 值的程序比较。
J Chem Inf Model. 2009 Dec;49(12):2801-12. doi: 10.1021/ci900289x.
2
Structure-based CoMFA as a predictive model - CYP2C9 inhibitors as a test case.基于结构的比较分子场分析作为一种预测模型——以CYP2C9抑制剂为例
J Chem Inf Model. 2009 Apr;49(4):853-64. doi: 10.1021/ci800313h.
3
Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: Impact of plasma and microsomal binding.
拮抗维生素 K 催化循环用于抗凝的结构基础。
Science. 2021 Jan 1;371(6524). doi: 10.1126/science.abc5667. Epub 2020 Nov 5.
4
Pattern-free generation and quantum mechanical scoring of ring-chain tautomers.环状-链状互变异构体的无模式生成及量子力学评分
J Comput Aided Mol Des. 2021 Apr;35(4):417-431. doi: 10.1007/s10822-020-00334-w. Epub 2020 Aug 24.
5
Tautomerism of Warfarin: Combined Chemoinformatics, Quantum Chemical, and NMR Investigation.华法林的互变异构:化学信息学、量子化学与核磁共振联合研究
J Org Chem. 2015 Oct 16;80(20):9900-9. doi: 10.1021/acs.joc.5b01370. Epub 2015 Sep 25.
6
Enumeration of ring-chain tautomers based on SMIRKS rules.基于SMIRKS规则的环链互变异构体计数
J Chem Inf Model. 2014 Sep 22;54(9):2423-32. doi: 10.1021/ci500363p. Epub 2014 Sep 9.
7
Applications of the InChI in cheminformatics with the CDK and Bioclipse.InChI 在 cheminformatics 中的应用,包括 CDK 和 Bioclipse。
J Cheminform. 2013 Mar 13;5(1):14. doi: 10.1186/1758-2946-5-14.
8
Functionalized 4-hydroxy coumarins: novel synthesis, crystal structure and DFT calculations.功能化 4-羟基香豆素:新型合成、晶体结构和 DFT 计算。
Molecules. 2011 Jan 7;16(1):384-402. doi: 10.3390/molecules16010384.
9
pK(a) based protonation states and microspecies for protein-ligand docking.基于 pK(a) 的蛋白配体对接质子化状态和微观种。
J Comput Aided Mol Des. 2010 Nov;24(11):935-42. doi: 10.1007/s10822-010-9385-x. Epub 2010 Sep 30.
在药物发现早期阶段,利用估算的物理化学性质作为预测肝脏清除率的一个组成部分:血浆和微粒体结合的影响。
Xenobiotica. 2009 Mar;39(3):227-35. doi: 10.1080/00498250802668863.
4
VKORC1: a warfarin-sensitive enzyme in vitamin K metabolism and biosynthesis of vitamin K-dependent blood coagulation factors.维生素K环氧化物还原酶复合体亚单位1:维生素K代谢及维生素K依赖的血液凝固因子生物合成中一种对华法林敏感的酶。
Vitam Horm. 2008;78:227-46. doi: 10.1016/S0083-6729(07)00011-8.
5
Structure and function of vitamin K epoxide reductase.维生素K环氧化物还原酶的结构与功能。
Vitam Horm. 2008;78:103-30. doi: 10.1016/S0083-6729(07)00006-4.
6
VKORC1 and the vitamin K cycle.维生素K环氧化物还原酶复合体亚单位1与维生素K循环
Vitam Horm. 2008;78:23-33. doi: 10.1016/S0083-6729(07)00002-7.
7
A Brief Account of a Disease in Cattle Simulating Hemorrhagic Septicaemia due to Feeding Sweet Clover.关于牛因喂食草木樨而患类似出血性败血病的一种疾病的简要记述
Can Vet J. 1984 Dec;25(12):453-5.
8
Potentiometric and spectrophotometric pKa determination of water-insoluble compounds: validation study in a new cosolvent system.水不溶性化合物的电位滴定法和分光光度法pKa测定:在一种新型共溶剂体系中的验证研究
Anal Chim Acta. 2007 Feb 5;583(2):418-28. doi: 10.1016/j.aca.2006.10.015. Epub 2006 Oct 18.
9
Synthesis and structure-activity relationships of novel warfarin derivatives.新型华法林衍生物的合成及其构效关系
Bioorg Med Chem. 2007 Mar 15;15(6):2414-20. doi: 10.1016/j.bmc.2007.01.014. Epub 2007 Jan 17.
10
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.华法林剂量以及细胞色素P450 2C9(CYP2C9)和维生素K环氧化物还原酶复合体亚单位1(VKORC1)的药物基因组学——原理与展望
Thromb Res. 2007;120(1):1-10. doi: 10.1016/j.thromres.2006.10.021. Epub 2006 Dec 11.